Latest news with #GlobalLeveragedFinanceConference
Associated Press
24-02-2025
- Business
- Associated Press
J.P. Morgan Increases Direct Lending Commitment to $50 Billion
J.P. Morgan announced today at its 30 th annual Global Leveraged Finance Conference a significant expansion to its private credit commitment. The firm is allocating $50 billion from its balance sheet, along with nearly $15 billion from multiple co-lenders. This strategic move is designed to extend the firm's direct lending capabilities and provide tailored private credit solutions to meet the evolving needs of clients. Since 2021, J.P. Morgan has successfully deployed over $10 billion across more than 100 private credit transactions, serving both corporate and sponsor clients. This latest commitment underscores the bank's dedication to being a leader in both the broadly syndicated and private credit markets. 'We aim to support our clients with products and solutions that best meet their capital structure needs, whether that's a direct or syndicated loan or a bond,' said Kevin Foley, global head of Capital Markets at J.P. Morgan. 'Our vast client relationships, paired with the size and scale of our origination capabilities, enable us to be a trusted financing source through a company's entire growth cycle.' The convergence of the broadly syndicated and private financing markets is creating unprecedented opportunities for clients, offering greater optionality and customized solutions to address their unique financing needs. As the leading investment bank with the #1 debt capital markets franchise and thousands of clients across the middle market and global corporate ecosystem, J.P. Morgan is uniquely positioned at the forefront of this evolution. 'We proudly bank 80,000 companies globally through our Commercial and Investment Bank, including 32,000 middle market clients across the U.S.,' said Jamie Dimon, Chairman and CEO of JPMorganChase. 'Extending this effort provides them with more options and flexibility from a bank they already know and see in their communities, and is known for being there during all market environments.' J.P. Morgan's enhanced direct lending platform is poised to drive significant impact, helping clients navigate today's dynamic financial landscape. The firm's strategic relationships with co-lenders further amplifies its ability to deliver comprehensive and competitive financing solutions. As private credit has grown exponentially to a $2 trillion market, direct lenders are sitting on hundreds of billions of dollars of dry powder to deploy. 'Pairing our vast origination platform with our lender client base has super charged our ability to deliver in size for borrowers and increased deal flow for lenders. Given our current success from our co-lending initiative, we continue to look for opportunities with new partners to augment our capabilities on large deals,' said Foley. Additional details around the co-lending arrangements have not been disclosed. About J.P. Morgan's Commercial & Investment Bank J.P. Morgan's Commercial & Investment Bank is a global leader in banking, payments, markets and securities services. Start-ups, companies, governments and institutions entrust us with their business in more than 100 countries worldwide. With $35.3 trillion of assets under custody and $1.01 trillion in deposits, the Commercial & Investment Bank provides strategic advice, raises capital, manages risk, offers payment solutions, safeguards assets and extends liquidity in global markets. Further information about J.P. Morgan is available at 212-270-7441 SOURCE: JPMorgan Chase & Co. Copyright Business Wire 2025. PUB: 02/24/2025 08:35 AM/DISC: 02/24/2025 08:35 AM
Yahoo
21-02-2025
- Business
- Yahoo
UPDATE - Magnera to present at JP Morgan's Global Leveraged Finance Conference
CHARLOTTE, N.C., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Magnera (NYSE: MAGN) will present at JP Morgan's Global Leveraged Finance Conference in Miami Beach, Florida. Magnera CEO, Curt Begle, and CFO & Treasurer, Jim Till, will participate on Tuesday, February 25, 2025, at 5:15 p.m. EST. About MagneraMagnera Corporation (NYSE: MAGN) was formed from the spinoff and merger of Berry Global Inc.'s Health, Hygiene and Specialties Global Nonwovens and Films Business with Glatfelter Corporation. The combined company serves 1,000+ customers worldwide, offering a wide range of products, including components for absorbent hygiene products, protective apparel, wipes, specialty building and construction products, and products serving the food and beverage industry. Magnera's purpose is to better the world with new possibilities made real. For more than 160 years, the company has delivered the material solutions their partners need to thrive. Through economic upheaval, global pandemics and changing end-user needs, we have consistently found ways to solve problems and exceed expectations. The distinct scale and comprehensive portfolio of products brings customers more materials and choices. With a combined legacy of resilience, Magnera builds personal partnerships that withstand an ever-changing world. Visit more information and follow @MagneraCorporation on social platforms. Investor Contact:Robert Weilminsterir@
Associated Press
14-02-2025
- Business
- Associated Press
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website. Details A replay of the event will be available on the investor relations website following the event. About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit and connect with us on LinkedIn. Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words 'will,' 'anticipates,' 'hopes,' 'expects,' 'intends,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'believes,' 'subject to' and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. SOURCE: Bausch Health Companies Inc.
